Recurv Pharma is developing a brand-new taxane therapy for the treatment of solid tumours.
Recurv Pharma has raised $24.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2023.
Recurv Pharma's investors include TVM Capital Life Science.
Recurv Pharma is headquartered in Wilmington, United States.
Recurv Pharma is developing a brand-new taxane therapy for the treatment of solid tumours.
Recurv Pharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Recurv Pharma — Funding & Investors." VCBacked, February 1, 2023, https://www.vcbacked.co/company/recurv-pharma. Accessed September 30, 2026.
VCBacked. (2023). Recurv Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/recurv-pharma
{{cite web |title=Recurv Pharma — Funding & Investors |url=https://www.vcbacked.co/company/recurv-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated